BrightInsight and Sanofi to Jointly Market Next Generation Digital...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

BrightInsight and Sanofi to Jointly Market Next Generation Digital Companion Application

Pharma Tech Outlook | Tuesday, January 25, 2022

Sanofi has chosen BrightInsight’s Platform to speed up the development of a medical device using one of their best-in-class software products.

FREMONT, CA: As new technologies and breakthroughs emerge, the medical and healthcare industries accelerate their technical advancements. With the advent of digital healthcare solutions, hospitals, clinics, and other healthcare institutions have significantly improved their patients' access to medical services and products. BrightInsight, Inc., the leading global platform for biopharmaceutical and medical device regulated digital health solutions, has formed a partnership with Sanofi, a global biopharmaceutical company focused on human health, to market a next-generation digital companion application for one of Sanofi's products. The BrightInsight® Platform has been chosen as the underlying infrastructure for accelerating the continuous development of one of Sanofi's best-in-class Software as a Medical Device offerings.

“BrightInsight has a track record of partnering with innovative and forward-looking biopharma leaders like Sanofi, who understand the value created by regulated digital health solutions that support treatment,” states Kal Patel, MD, CEO & Co-Founder, BrightInsight. “Our deep experience launching Software as a Medical Device, regulatory expertise, and robust platform enable us to support Sanofi's goals of accelerating time to market and delivering an exceptional patient experience in a manner compliant to the various critical and complex regulatory, quality, privacy, and security requirements.”

Patients will easily access services and assistance from therapy onboarding to chronic disease management thanks to the BrightInsight® Platform that Sanofi's is using for its digital companion application. Users will be able to take control of their complex illnesses with personalized profiles and material, as well as step-by-step instructions for administering medicine. An integrated ecosystem of third-party systems and a patient mobile app compose the solution. Once it's available in the US, the app will spread to other countries.

Emmanuel Frenehard, Global Head of Digital at Sanofi, states, “BrightInsight was selected to help Sanofi build and launch Sanofi's latest Software as a Medical Device, providing a disease management solution for one of its most important treatments. The partnership supports Sanofi's digital strategy to create more engaging patient experiences with the goal to improve treatment outcomes.”

Weekly Brief

Read Also